HRTX — Heron Therapeutics Share News
0.000.00%
Last trade - 00:00- $57.49m
- $158.52m
- $154.90m
U.S. STOCKS ON THE MOVE-Stoke Therapeutics, Foot Locker, Marvell
U.S. STOCKS ON THE MOVE-Nano Nuclear, JetBlue, Cross Country
U.S. STOCKS ON THE MOVE-Eli Lilly, GM, Dollar Tree
U.S. STOCKS ON THE MOVE-Salesforce, Heron Therapeutics, Novavax
Heron Therapeutics jumps on favorable court ruling over Cinvanti patents
Brief: Heron Therapeutics Inc U.S. District Court Upholds Validity Of Cinvanti Patents
U.S. RESEARCH ROUNDUP- AMN Healthcare Services, Chart Industries, Home Depot
Heron Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Heron Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Heron Therapeutics Announces Appointment Of Michael Kaseta To Board Of Directors
Brief: Heron Therapeutics Reaffirms Availability And Ample Supply Of Cinvanti®, Sustol®, And Aponvie® As Alternatives During The Potential Shortage Of Intravenous Fluids
Brief: Heron Therapeutics Announces FDA Approval Of The Prior For Zynrelef
Heron Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Heron Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy
Brief: Heron Therapeutics Announces Acceptance Of Prior Approval Supplement Application For ZYNRELEF Vial Access Needle
Brief: Heron Therapeutics Announces Prior Approval Supplement Submission To The FDA For Zynrelef® Vial Access Needle ("Van")
Heron Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Heron Therapeutics Inc reports results for the quarter ended in December - Earnings Summary